Phase I Study of Lysine-Specific Demethylase 1 Inhibitor, CC-90011, in Patients with Advanced Solid Tumors and Relapsed/Refractory Non-Hodgkin Lymphoma

• Published in: Clinical cancer research Vol. 27; no. 2; pp. 438 - 446
• Main Authors: Hollebecque, Antoine, Salvagni, Stefania, Plummer, Ruth, Isambert, Nicolas, Niccoli, Patricia, Capdevila, Jaume, Curigliano, Giuseppe, Moreno, Victor, Martin-Romano, Patricia, Baudin, Eric, Arias, Marina, Mora, Sheila, de Alvaro, Juan, Di Martino, Jorge, Parra-Palau, Josep L, Sánchez-Pérez, Tania, Aronchik, Ida, Filvaroff, Ellen H, Lamba, Manisha, Nikolova, Zariana, de Bono, Johann S
• Format: Journal Article
• Language: English
• Published: United States 15.01.2021
• Subjects: Adult; Aged; Antineoplastic Agents - adverse effects; Antineoplastic Agents - pharmacokinetics; Antineoplastic Agents - therapeutic use; Area Under Curve; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Fatigue - chemically induced; Female; Humans; Lymphoma, Non-Hodgkin - drug therapy; Lymphoma, Non-Hodgkin - pathology; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasms - drug therapy; Neoplasms - pathology; Organic Chemicals - adverse effects; Organic Chemicals - pharmacokinetics; Organic Chemicals - therapeutic use; Thrombocytopenia - chemically induced; Treatment Outcome; Young Adult
• ISSN: 1078-0432; 1557-3265
• DOI: 10.1158/1078-0432.CCR-20-2380

Lysine-specific demethylase 1 (LSD1) is implicated in multiple tumor types, and its expression in cancer stem cells is associated with chemoresistance. CC-90011 is a potent, selective, and reversible oral LSD1 inhibitor. We examined CC-90011 in advanced solid tumors and relapsed/refractory (R/R) non-Hodgkin lymphoma (NHL). CC-90011-ST-001 (NCT02875223; 2015-005243-13) is a phase I, multicenter, first-in-human dose-escalation study. Nine dose levels of CC-90011 (1.25-120 mg) given once per week were explored. Primary objectives were to determine safety, maximum tolerated dose (MTD), and/or recommended phase II dose (RP2D). Secondary objectives were to evaluate preliminary efficacy and pharmacokinetics. Fifty patients were enrolled, 49 with solid tumors (27 neuroendocrine tumors/carcinomas) and 1 with R/R NHL. Median age was 61 years (range, 22-75). Patients received a median of three (range, 1-9) prior anticancer regimens. The RP2D was 60 mg once per week; the nontolerated dose (NTD) and MTD were 120 mg once per week and 80 mg once per week, respectively. Grade 3/4 treatment-related toxicities were thrombocytopenia (20%; an on-target effect unassociated with clinically significant bleeding), neutropenia (8%; in the context of thrombocytopenia at the highest doses), and fatigue (2%). The patient with R/R NHL had a complete response, currently ongoing in cycle 34, and 8 patients with neuroendocrine tumors/carcinomas had stable disease ≥6 months, including bronchial neuroendocrine tumors, kidney tumor, and paraganglioma. CC-90011 is well tolerated, with the RP2D established as 60 mg once per week. The MTD and NTD were determined to be 80 mg once per week and 120 mg once per week, respectively. Further evaluation of CC-90011 is warranted.